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the care pathway to ensure rapid assessment and treatment for TIA patients would 
avoid 128 future stroke events over three years. As a result, the costs associated with 
the reconﬁguration of the TIA patient care pathway would be partially offset by 
savings in acute stroke management costs. CONCLUSIONS: Our model suggests that 
implementing a revised TIA care pathway in Hungary would result in a reduction of 
TIA-related recurrent strokes, leading to reduced costs associated with the acute 
management of stroke. This would partially offset the costs of establishing rapid 
assessment and treatment clinics for patients experiencing TIA.
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OBJECTIVES: Preeclampsia, a leading cause of maternal and perinatal morbidity 
and mortality, is only detected after the onset of clinical symptoms. Earlier diagnosis 
may be possible with a new serum test using soluble fms-like tyrosine kinase-1 (sFlt-1) 
and placental growth factor (PlGF) biomarkers. Clinical and economic beneﬁts may 
result from appropriate detection and management of subclinical cases, and from 
averting costs associated with incorrect diagnoses. We evaluated the ﬁnancial impact 
of the novel test versus standard care from a UK health care payer perspective. 
METHODS: We developed a decision-analytic model of the clinical and economic 
impact resulting from improved sensitivity and speciﬁcity of the new test over current 
diagnostic practice. Acute management and follow-up costs were associated with 
true positive, true negative, false positive, and false negative diagnoses. The base- 
case analysis assumed that, of all pregnant women, 15% present with risk factors 
while 85% do not. The CHF 52 (£-equivalent) test was assumed to be administered 
after 20 weeks of gestation. True positive and false negative patients were assumed 
to enter one of four health states: mild preeclampsia; severe preeclampsia; eclampsia; 
or death. Data pertaining to treatment practices, health care resource utilization, 
incidence, costs, and funding for detection and management of preeclampsia in the 
UK were obtained through interviews with clinicians, laboratory managers, and health 
care payers in the UK. Additional data were obtained from published literature and 
public databases. RESULTS: Model results suggest that when used for screening, the 
novel test would reduce false negative diagnoses of preeclampsia by 67% and 
false positives by 71%. Costs per patient are estimated to be £1781 with the novel 
test and £2726 with standard practice, saving an estimated £945 per patient given the 
novel test. CONCLUSIONS: This test has the potential to improve detection and 
management of preeclampsia translating into substantial cost savings for UK health 
care payers.
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OBJECTIVES: Due to lack of awareness of Transient Ischaemic Attack (TIA) symp-
toms, many patients may not immediately seek medical help, creating delay in access 
to treatment. The UK EXPRESS study by Rothwell et al. (Lancet 2007;370:1432–42) 
demonstrated that a greater focus on rapid assessment and management of TIA could 
signiﬁcantly reduce subsequent stroke rates. With nearly 35,000 cerebrovascular 
disease-related deaths in Spain last year, we wanted to examine how a shift in care 
pathways towards that outlined in the EXPRESS study could affect stroke rates, 
and explore the ﬁnancial implications of such a shift in care pathway. METHODS: 
We developed an economic model to estimate the costs and savings associated 
with establishing a rapid assessment and treatment clinic for patients with suspected 
TIA in Spain, in line with phase 2 of the EXPRESS study. We used a population     
of 1,000,000 people with an assumed annual incidence of TIA of 0.021%. 
Current management was based on ESO guidelines and common clinical practice. 
We included direct costs associated with care (medications, diagnostics and staff—
where data were unavailable, converted UK costs were used), and modeled the    
 impact of changing management over a three-year time horizon. RESULTS: For an 
assumed population of 1,000,000, changing the care pathway care to ensure rapid    
assessment and treatment for TIA patients would result in 66 future stroke events    
avoided over 3 years. As a result, the costs associated with changing the pathway of 
care for TIA would be partially offset by savings in acute management costs associated     
with stroke. CONCLUSIONS: Our model suggests that implementing a revised TIA 
care pathway in Spain would reduce the number of TIA-related recurrent strokes, 
leading to reduced costs associated with acute stoke management. This would partially 
offset the cost of establishing rapid assessment and treatment clinics for patients 
experiencing TIA.
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OBJECTIVES: Syncope that remains unexplained after a conventional evaluation is a 
common and vexing medical problem. Implantable loop recorder (ILR) is a new 
diagnostic method in diagnosis of recurrent syncope with unexplained etiology (NO). 
The aim of this analysis was to estimate the impact of ILR reimbursement in NO 
diagnostics on budget of public payer’s in Poland. METHODS: The analysis was 
performed in 5-year time horizon from the public payer’s perspective. Information 
regarding target population and medical resources was extracted from literature and 
registry PL-US. Data in the registry PL-US were collected during 2006–2008 in 18 
Polish centers. Cost data were obtained from the National Health Fund. In the analysis 
two scenarios were compared: actual (current situation with ILR reimbursement only 
in special cases) and prognostic (after ILR reimbursement). In the prognostic scenario 
two ﬁnancing options of monitoring of patients after ILR implantation were distin-
guished—AOS and KAOS. One-way sensitivity analysis were performed for the key 
input parameters. RESULTS: The number of target population for ILR implantation 
in Poland is stable, approximately 2370 patients. In actual scenario estimated annual 
public payer expenditure for NO diagnostics in each year 2010–2014 is approximately 
9.00 mPLN, where cost of ILR is 0.25 mPLN. Assuming reimbursement of ILR esti-
mated public payer expenditure for NO diagnostics in option AOS is 9.77 mPLN in 
year 2010 and 16.76 mPLN in year 2014, where ILR costs is 1.44 mPLN and 
11.34 mPLN, respectively. In option KAOS public payer expenditure is 9.86 mPLN 
in year 2010 and 18.49 mPLN in year 2014, where ILR costs is 1.53 mPLN and 
13.07 mPLN, respectively. CONCLUSIONS: Our ﬁndings suggest that decision con-
cerning ILR reimbursement should not lead to increase total expenses on the NO 
diagnostics for public payer more than 0.95 mPLN in year 2010 and 10.00 mPLN in 
year 2014.
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OBJECTIVES: Budget impact models for new drugs provide estimates of the changes 
in annual costs of drug therapy as well as estimates in the changes in other health care 
costs attributable to the underlying disease or the side effects of treatment. METHODS: 
In this study we estimated the annual change in disease and side-effects costs associated 
with the addition of prasugrel to a drug formulary for treatment of those with acute 
coronary syndrome (ACS) undergoing a percutaneous coronary intervention in a 
managed care organization with 1,000,000 covered lives. The model compared the 
annual costs in each of the ﬁrst three years after addition of prasugrel to the formulary 
assuming a maximum treatment share of 50% after 1 year. The only alternative treat-
ment was clopidogrel and people already being treated with clopidogrel were not 
switched to prasugrel. The relative risk of subsequent cardiovascular events and bleed-
ing events for each drug were taken from a head-to-head 15-month clinical trial. The 
risk of cardiovascular events reverted to the risk of those taking only aspirin for those 
discontinuing prasugrel or clopidogrel treatment. RESULTS: The estimated numbers 
of cardiovascular events (bleeding events) after an ACS episode with prasugrel on the 
formulary in the ﬁrst three years were 541 (36), 528 (42), and 525 (43) respectively 
and without prasugrel were 548 (35) in all three years. The annual reductions in 
disease- and bleeding-related costs in the ﬁrst 3 years after adding prasugrel to the 
formulary were estimated to be $141,907, $419,377, and $488,119 respectively. 
CONCLUSIONS: Using a more effective dual oral antiplatelet regimen is likely 
to result in lower disease-related costs that are not offset by higher bleeding-related 
costs. The disease- and bleeding-event cost savings estimated in the model should be 
included in a comprehensive estimate of the budget impact of adding prasugrel to a 
formulary.
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OBJECTIVES: Atrial ﬁbrillation (AF) is frequent cardial disease. The prevalence in 
Slovak republic is estimated about 1% in adult population. The most potential risk of 
AF is stroke, Ist incidence is estimated about 2.3% e.g. more than six times as in stan-
dard population. The main objective of this study was to determine direct medical costs 
related to AF and the possible budget impact of new treatment by dronedaron. 
METHODS: Direct medical costs were evaluated from data collected in 2007 from the 
General Health Insurance Company, the largest one in Slovakia, covering 55% of 5.4 
million inhabitants. The results were recalculated to the total population. The costs 
were quoted in 2007 prices. RESULTS: The AF costs were a16,685,720; in out-patients 
care they were a1,384,743; in hospital care they were a12,135,196; in drug consump-
tion they were a2,013,127 and in diagnostic procedures they were a1,152,653. Totally 
it was 0,556% of total Slovakia health care budget. The cost of treating the patients 
with stroke was a30,098,891, which is 1.003% of total Slovakia health care budget. 
Dronedaron is new drug for the treatment of AF. The outcomes from the ATHENA 
study showed 26% risk reduction of hospitalization and 34% risk reduction of stroke. 
The dronedaron usage can reduce the health care costs by a2,872,370 per year, i.e. 
0.096% from total budget. CONCLUSIONS: The direct costs associated with AF 
comprise an important part of total health care budget in Slovakia. They signalize 
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the need to establish effective strategies for AF. Clinical outcomes from the ATHENA 
study adapted to Slovak conditions show the actual potential of dronedaron to be 
a cost-effective way in reducing AF complications and decreasing health care 
expenditures.
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OBJECTIVES: Cardiac Multi-Slice Computed Tomography (MSCT) has been dem-
onstrated as a valid diagnostic tool for coronary artery disease (CAD) especially due 
to its higher comparative accuracy. Consequently, there is mutual agreement on its 
use following a non-interpretable or equivocal stress-test (exercise, perfusion or stress-
echo) result; however, its frequent use as ﬁrst-step investigation contributes to the 
controversy on which strategy really maximizes patient outcomes. Using data of a 
regional registry, we investigated the optimal application of MSCT in patients with 
suspected CAD. METHODS: During 2007, 566 patients with suspected CAD or stable 
angina underwent MSTC in six different public structures in Emilia-Romagna; after 
applying exclusion criteria (previous hospitalization for Acute Myocardial Infarction 
and/or revascularization; MSCT performed in inpatient setting), 350 subjects (209 
with and 141 without a previous stress-test result, respectively) were considered eligi-
ble. All events of interest, such as death, hospitalizations, diagnostic procedures, visits 
and cardiovascular drugs utilization were traced for one year. Direct costs were evalu-
ated from the perspective of the Regional Health Service (RHS). RESULTS: Except 
for hyperlipidemia (p  0.0058) and diuretics consumption (p = 0.006), all baseline 
characteristics were similar between the two groups. No relevant differences were 
found in all endpoints except for the average number of cardiovascular-related hospi-
talizations (0.46 vs. 0.33; p  0.0013), which was signiﬁcantly lower in the 
“stresstestMSCT” group. Notably, hospitalizations alone accounted for 90% of total 
health care expenditures (a1.018.054 for all 350 patients). The sensitivity analysis 
(based on 5000 bootstrap samples) indicated a mean cost difference of a513 / 22 
(CI 95%) and a mean hospitalizations difference of 0.13 / 0.003 in favor of the 
“stresstestMSCT” strategy (0.46 vs. 0.33; p = 0.66), which showed a probability of 
being cost effective of 0.86 (WTP  a10,000). CONCLUSIONS: Using MSTC after 
stress-test is likely to reduce the risk of hospitalization and additionally provides good 
value for money from the perspective of the RHS.
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OBJECTIVES: Chronic heart failure (CHF) is a major health issue because of its 
growing prevalence, morbimortality and associated resource consumption. Beta block-
ers have been shown to be effective and cost-effective therapies for CHF. The aim is 
determining what beta blocker constitutes the most efﬁcient therapy for CHF patients 
in Spain. METHODS: Systematic review of primary (clinical trials) and secondary 
(meta-analyses, clinical practice guidelines, economic assessments and reports from 
independent local agencies) evidence on beta blockers for CHF issued before April 
2009. Once that efﬁcacy of each beta blocker was established, local drug databases 
were accessed in order to estimate the updated annual cost of each therapy and daily 
dose in Spain. RESULTS: Given their similar efﬁcacy [death RR: bisoprolol: 0.66, 
p  0.0001; metoprolol: 0.66, p  0.0001; carvedilol: 0.65, p  0.005, nebivolol: 0.88, 
p  0.21] and safety proﬁles, international clinical guidelines on Cardiology recom-
mend bisoprolol, metoprolol, carvedilol and nebivolol as ﬁrst choice therapies for CHF 
(class I and level of evidence A). Signiﬁcant annual drug cost differences for bisoprolol 
have been previously reported by independent Spanish agency GENESIS and are con-
ﬁrmed with 2009 prices [bisoprolol: a22.36–114.58; metoprolol: a30.20–241.63; 
carvedilol: a39.24–264.62; nebivolol: a52.50–420.01]. When hospitalization costs are 
included, a recent meta-analysis of beta blockers for CHF in Spain proved that biso-
prolol is not only the cheapest beta blocker therapy but even a more efﬁcient alterna-
tive than placebo [2005 prices: bisoprolol: a414.28; metoprolol: a507.64; carvedilol: 
a888.50; placebo: a484.96]. Budget impact analysis yields that bisoprolol implies a 
saving of 26–53% of metoprolol cost of therapy per year and patient, 43–57% when 
compared to carvedilol and 57–73% versus nebivolol. CONCLUSIONS: According 
to recently updated Cardiology guidelines and evidence issued by independent bodies, 
bisoprolol gathers pharmacologic, legal and pharmacoeconomic characteristics that 
conﬁrm their being the most efﬁcient beta blocker (both in terms of cost-beneﬁt and 
cost-effectiveness) for CHF patients in Spain.
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OBJECTIVES: For patients with acute coronary syndrome (ACS) treated with percu-
taneous coronary intervention, 12-month dual antiplatelet (thienopyridine plus 
aspirin) treatment is recommended. A phase III clinical trial (TRITON) in ACS patients 
with planned PCI demonstrated superiority of prasugrel versus clopidogrel on the 
primary composite endpoint (myocardial infarction, stroke, cardiovascular death) but 
also higher bleeding risk. This model was designed to estimate the impact on the hos-
pital budget of the national health insurance of substituting prasugrel to clopidogrel. 
METHODS: The budget impact model was based on index and recurrent hospital 
stays related to cardiovascular and bleeding causes from the economic cohort of 
TRITON (N  6705) with a mean of 380 days of follow-up. A speciﬁc DRG code 
was attributed to each stay and transcoded to French DRG. A weighted cost was cal-
culated based on public and private French DRG ofﬁcial tariff (2007), including an 
average cost for stents and intensive care unit costs. In-hospital costs of thyenopyridine 
use were not included in the analysis. The time horizon was 1-year. Budget impacts 
were calculated for two groups: A) Patients without history of transient ischemic 
attack (TIA) and stroke), B) Patients without TIA/stroke and weight 60 kg and 75 
years-old. RESULTS: For Group A the costs for all patients for one year were 
a25,719,447.48 for prasugrel and a26,123,027.37 for clopidogrel, for Group B they 
were respectively a20,897,133.23a and a21,096,756.42. Predominant differences 
were on costs related to recurrent hospital stays (respectively for A: a5,501,347.76 
and a6,053,118.09a; B: 4,354,983.17 and 4,827,315.74). Substituting prasugrel to 
clopidogrel would result in daily savings of: A) a0.45 per patient B) 0.46a per patient. 
CONCLUSIONS: This budget impact model showed that prevention of recurrent 
events with prasugrel generates savings that could offset to some extent potential price 
differences with clopidogrel.
PCV61
COST OF EXERCISE TRAINING AND ITS IMPACT ON MEDICAL 
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OBJECTIVES: The HF-ACTION study was a controlled trial to evaluate efﬁcacy and 
safety of exercise training in patients with heart failure. A prospective economic evalu-
ation was planned alongside the trial to evaluate resource use and costs associated 
with exercise training. METHODS: Between April 2003 and February 2007, HF-
ACTION randomized 2331 heart failure patients with NYHA Class II to IV to usual 
care plus exercise training, consisting of 36 supervised sessions followed by home-
based training, versus usual care alone. Data on medical resource use and hospital 
bills were collected throughout the trial. Intervention-related costs were estimated 
using patient-level data from the trial, administrative records, and published unit costs. 
Counts of resource use were compared using negative binomial regression models. 
Conﬁdence intervals for cost differences were derived using nonparametric bootstrap-
ping. RESULTS: Mean follow-up was 2.5 years in both groups. There were 2297 
hospitalizations in the exercise training group (n  1159) and 2332 in the usual care 
group (n  1172)(P  0.924). The mean number of inpatient days was 13.6 (SD  
27.0) and15.0 (SD  31.4) days in the exercise training and usual care groups, respec-
tively (P  0.21). Additional measures of medical resource use, including urgent care 
visits, outpatient visits and procedures, home IV therapy, skilled nursing and rehabili-
tative care were similar between groups, with the exception that fewer patients in the 
exercise training group underwent high-cost inpatient procedures including heart 
transplant and/or placement of a left ventricular assist device (n  44 [3.7%] vs. 
n  31 [2.7%], P  0.14). Total direct medical costs were estimated at $50,857 (SD  
81,488) in the exercise training group and $56,177 (SD  92,749) in the usual care 
group (95% CI for difference: $12,755 to $1547). Direct cost of exercise training 
was estimated at $1006 (SD  337). CONCLUSIONS: Exercise training had little 
systematic impact on medical resource use overall, but the cost of exercise training 
may have been offset through a reduction in high-cost procedures.
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OBJECTIVES: Estimate annual direct costs for privately-insured U.S. pulmonary 
arterial hypertension (PAH) patients and matched controls. METHODS: From a pri-
vately-insured claims database (8 million beneﬁciaries, 2002–2007), 951 PAH 
